THIS MESSAGE (MATERIAL) IS CREATED AND (OR) DISTRIBUTED BY A FOREIGN MASS MEDIA PERFORMING THE FUNCTIONS OF A FOREIGN AGENT AND (OR) A RUSSIAN LEGAL ENTITY PERFORMING THE FUNCTIONS OF A FOREIGN AGENT.
The Federal Medical and Biological Agency (FMBA) has submitted an application to the Ministry of Health to start a clinical trial of the Mir-19 coronavirus drug for use outside hospitals.
According to the press service of the department, the drug is planned to be tested for use “in the outpatient setting” in the first days after the patient is confirmed to have covid.
Recall that Mir-19 inhalation drug was registered on December 22, 2021 after two phases of clinical trials, but only for use in a hospital. In order for the medicine to become available for purchase at a pharmacy during home treatment, a special study must be carried out. About 1 thousand volunteers should take part in post-registration studies of the drug.
All stages of production of Mir-19 take place at the site of the St. Petersburg Research Institute of Vaccines and Serums FMBA.
If the drug is highly effective, FMBA plans to create two more forms of the drug in the form of a spray for post-exposure prophylaxis. This medicine can be used in order to prevent the development of the disease if a person has previously been in contact with an infected coronavirus.
Source: Rosbalt
Tristin is an accomplished author and journalist, known for his in-depth and engaging writing on sports. He currently works as a writer at 247 News Agency, where he has established himself as a respected voice in the sports industry.
